Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) November 25, 2011 -- The orphan autoimmune disorder therapeutics market is one of the steadily growing markets in autoimmune therapeutics and is expected to show a significant growth in forecast period. The ITP and ALS market are the leading contributors to the global orphan autoimmune disorder therapeutics market in 2010. Moreover, the market for myasthenia gravis has shown a steady growth in terms of revenue and is expected to grow at a greater pace in the future.

The ITP market has witnessed a significant growth between 2008 and 2010 due to the launch of two novel second-line therapies, namely Nplate (romiplostim) and Promacta (eltrombopag), which stimulate platelet production in adults with chronic ITP. The ALS market has also shown a steady growth in terms of revenue in the presence of Rilutek, which is the only FDA approved drug for this indication. The myasthenia gravis market is dominated by generics and over-the-counter (OTC) drugs. However the approval of Prograf (tacrolimus hydrate) in Japan (October 2009) and the future launch of Venoglobulin-IH, a human immunoglobulin therapy is expected to boost the myasthenia gravis market in the forecasted period

The ITP market has shown significant growth between 2008 and 2010 as two new drugs

(thrombopoietins), namely Nplate and Promacta, were launched. Moreover, these drugs have shown a substantial growth in their revenue, which boosted the ITP market during this period (2008-2010). In addition, three immunoglobulin products (Rhophylac, Carimune and Privigen) of CSL Behring were launched with ITP as their extended indication. With long-term patent protection and exclusivity of Nplate and Promacta and existing immunoglobulin therapies, the global ITP market is anticipated to grow at a steady pace during the forecast period.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Orphan-Autoimmune-Disorders-to-2017-Strong-Performance-by-Nplate-and-Promacta-and-Future-Launches-of-Immunoglobulin-Therapies-will-Drive-the-ITP-market&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&CompanyID=fprco

GBI Research, the leading business intelligence provider, has released its latest research, “Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market”. It provides in-depth analysis of the drivers and barriers that affect the global orphan autoimmune disorders therapeutics market. The report analyzes the markets for orphan autoimmune disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the key geographies as well as the leading therapeutic segments (ITP, myasthenia gravis and ALS). Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Orphan-Autoimmune-Disorders-to-2017-Strong-Performance-by-Nplate-and-Promacta-and-Future-Launches-of-Immunoglobulin-Therapies-will-Drive-the-ITP-market&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare&CompanyID=fprco

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477

Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

Orphan Autoimmune Disorders     Pharmaceuticals and Healthcare